Comparative product overview
Select parameters for ASPARLAS®, ONCASPAR®, and RYLAZE™
ONCASPAR® pegaspargase1 | |
|---|---|
Indication in ALL | PrONCASPAR® (pegaspargase) is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with ALL |
Half-life |
Half-life based on PK data after a single dose of ONCASPAR® 2500 U/m2 |
Recommended dose | For patients <21 years of age with:
For patients >21 years of age:
|
Shelf life | Proposed shelf life of 8 months. Keep refrigerated prior to use at 2°C to 8°C. Do not freeze or shake. Store vials in the original package to protect from light. Discard any unused portion. Do not use beyond the expiration date printed on the carton or vial. |
Data from separate Product Monographs and regulatory documents; comparative clinical significance has not been proven.
Consult the individual Product Monographs for complete dosing and administration information.
Dosing protocols for ASPARLAS®*, ONCASPAR®†, and RYLAZE™‡
Product | Week 1 |
|---|---|
ONCASPAR®1 | 
or  |
ASPARLAS®3 |
|
RYLAZE™4 |
|
*The recommended dose of ASPARLAS® is 2500 U/m2 IV no more than every 21 days.
†The recommended dose of ONCASPAR® for patients with BSA >0.6 m2 and aged ≤21 years is 2500 U (equivalent to 3.3 mL ONCASPAR®)/m² body surface area IV or IM every 14 days.
‡The recommended dosage of RYLAZE™ is 25 mg/m2 on Monday and Wednesday and 50 mg/m2 IM on Friday, for a total of six doses to replace each planned dose of pegaspargase.
= intravenous infusion
= intramuscular
Data from separate Product Monographs; comparative clinical significance has not been proven.
See individual Product Monographs for complete dosing and administration information.
Learn more about Servier Canada’s treatment options in ALL
Consult the ONCASPAR® Product Monograph
Have you heard about ASPARLAS®?
ASPARLAS® (calaspargase pegol for injection) is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of ALL in pediatric and young adult patients age 1 to 21 years.
aBFM: augmented Berlin-Frankfurt-Münster; ALL: acute lymphoblastic leukemia; BSA: body surface area; CNS: central nervous system; CSF: cerebrospinal fluid; DFCI: Dana-Farber Cancer Institute; ELISA: enzyme-linked immunosorbent assay; IM: intramuscular; IV: intravenous; PD: pharmacodynamics; PK: pharmacokinetics; NCCN: National Comprehensive Cancer Network®; TDM: therapeutic drug monitoring.
* Clinical significance has not been established.
† Comparative clinical significance has not been established.
‡ Fictitious cases. May not be representative of all patients.
§ Native E. coli L-asparaginase is not available in Canada.
References:
- ONCASPAR® Product Monograph. Servier Canada. August 20, 2024.
- ONCASPAR_CPID Redacted.
- ASPARLAS® Product Monograph. Servier Canada. March 8, 2024.
- RYLAZE™ Product Monograph. Jazz Pharmaceuticals Canada Inc.
- NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Lymphoblastic Leukemia V.2.2024. Available at: https://www.nccn.org/professionals/physician_gls/pdf/all.pdf. Accessed November 8, 2024.
- Vrooman LM et al. Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukemia: Results of DFCI 11-001. J Clin Oncol. 2021;39(31):3496–3505.
